Skip to Main Content

Advertisement

Skip Nav Destination

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Clin Cancer Res OF1–OF14.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal